Symposia: Acute Myeloid Leukemias: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, adult, epidemiology, Clinical Practice (Health Services and Quality), Translational Research, Clinical Research, health outcomes research, Diseases, patient-reported outcomes, real-world evidence, survivorship, Myeloid Malignancies, Human
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, adult, epidemiology, Clinical Practice (Health Services and Quality), Translational Research, Clinical Research, health outcomes research, Diseases, patient-reported outcomes, real-world evidence, survivorship, Myeloid Malignancies, Human
Sunday, December 11, 2022: 12:00 PM-1:30 PM
271-273
(Ernest N. Morial Convention Center)
Moderators:
Lindsay Wilde, MD, Thomas Jefferson University
and
Brian A. Jonas, MD, PhD, University of California Davis School of Medicine
Disclosures:
Jonas: Rigel: Consultancy, Other: Travel Reimbursement; AbbVie: Consultancy, Other: Travel Reimbursement, Research Funding; GlycoMimetics: Consultancy, Other: protocol steering committee , Research Funding; Gilead: Consultancy, Other: data monitoring committee , Research Funding; BMS: Consultancy, Research Funding; 47: Research Funding; Genentech: Consultancy, Research Funding; Jazz: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Servier: Consultancy; Takeda: Consultancy; Tolero: Consultancy; Treadwell: Consultancy; Accelerated Medical Diagnostics: Research Funding; Amgen: Research Funding; AROG: Research Funding; BMS: Consultancy, Research Funding; Celgene: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; F. Hoffmann-La Roche: Research Funding; Forma: Research Funding; Roche: Research Funding; Hanmi: Research Funding; Immune-Onc: Research Funding; Incyte: Research Funding; Loxo Oncology: Research Funding; LP Therapeutics: Research Funding; Pharmacyclics: Research Funding; Sigma Tau: Research Funding.
This session includes abstracts that summarize key clinical findings and longer term outcomes in clinically, histologically, and genomically defined subgroups of patients with acute myeloid leukemia.
12:00 PM
12:15 PM
12:30 PM
12:45 PM
1:00 PM
1:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH